2024-11-07 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 761.23% compared to VOO's 134.06%. This translates to a substantial outperformance gap of 627.17%. 

**Alpha and Beta Analysis:**

* **Alpha:** LLY consistently demonstrates strong alpha, indicating its outperformance over the benchmark, particularly in recent years (2018-2024).
* **Beta:** LLY has a beta consistently below 1 (ranging from 0.5 to 0.8), suggesting less volatility than the overall market.

**2. Recent Price Movement:**

* **Closing Price:** 806.06 (Last-market: 769.1)
* **5-day Moving Average:** 821.54
* **20-day Moving Average:** 888.31
* **60-day Moving Average:** 910.4

LLY's recent price movement suggests a short-term downtrend as the current price is below all three moving averages, with the 5-day moving average showing a faster decrease than the 20-day and 60-day moving averages.

**3. Technical Indicators:**

* **RSI:** 11.69, indicating oversold conditions.
* **PPO:** -1.31, suggesting a downtrend.
* **Delta_Previous_Relative_Divergence:** -14.38 (-), indicating short-term downward momentum.
* **Expected_Return:** 97.94%, suggesting a potential for long-term (2+ years) outperformance against the S&P 500.

**4. Recent Earnings and Outlook:**

* **Recent Earnings:** LLY reported solid earnings in Q3 2024, exceeding analyst expectations with an EPS of 1.08 compared to an estimated 1.05. Revenue also surpassed expectations at $11.44 billion compared to $11.3 billion. This consistent performance suggests LLY's strong financial position and robust growth potential.

**5. Financial Information:**

**Revenue and Profitability:**

* LLY has maintained consistent revenue growth and high profit margins in recent quarters.
* The company's profitability remains strong, consistently above 80% profit margin.

**Capital and Profitability:**

* LLY demonstrates strong capital growth and profitability, with ROE consistently above 15% in the past few quarters, showcasing efficient capital management.

**6. News and Recent Issues:**

* **Recent Earnings News:** Recent earnings reports from Eli Lilly have generally been positive, with the company consistently exceeding expectations.
* **Market Outlook:** Analysts generally remain optimistic about LLY's future performance, with a strong focus on the company's innovative pipeline and promising new drug launches.
* **Analyst Opinions:** Most analysts recommend a "buy" or "strong buy" rating for LLY, highlighting its long-term growth potential and potential for market outperformance.

**7. Overall Analysis:**

* LLY has consistently outperformed the S&P 500 with strong growth and profitability.
* The company's recent earnings performance has been robust, exceeding analyst expectations.
* Technical indicators suggest a potential short-term pullback, but the long-term outlook remains positive.
* Strong fundamentals, a robust pipeline, and a favorable market environment point to LLY as a compelling investment opportunity.

**8. Conclusion:**

Eli Lilly and Co (LLY) remains a strong performer with solid fundamentals, a robust pipeline, and a favorable market environment. While recent technical indicators signal a possible short-term pullback, the long-term outlook for LLY remains positive, making it a promising investment for investors seeking long-term growth and outperformance. 
